Our research indicates that the principal active constituents of QJSXP, including Luteolin, Ellagic acid, Kaempferol, Apigenin, and Eupafolin, may influence ITP by modulating signalling pathways such as Pathways in Cancer, the PI3K-Akt signalling pathway, MicroRNAs in cancer, and the MAPK signalling pathway, potentially via targets such as CYP1B1, SYK, FYN, and STAT3, as determined through target prediction, protein interaction network construction, and GO/KEGG pathway enrichment analysis. The gene discussed is FYN; the disease is autoimmune thrombocytopenic purpura.